Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy

Daixi Ren(Central South University), Wei Xiong(Central South University), Yunhua Chen(Key Laboratory of Guangdong Province), Yujuan Zhou(Hunan Cancer Hospital), Xiaoxu Wei(Central South University), Qianjin Liao(Hunan Normal University), Bo Xiang(Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital), Zhaoyang Zeng(Shenzhen Academy of Robotics), Yongzhen Mo(Central South University), Guiyuan Li(Xuzhou Medical College), Xin Ye(Beihua University), Yong Li(Baylor College of Medicine), Xiaoling Li(Southwest University), Jie Wang(Fujian Medical University), Hui Wang, Ming Zhou(Central South University), Boyao Yu(Central South University), Yuze Hua(Chinese Academy of Medical Sciences & Peking Union Medical College), Chunwei Li(Sun Yat-sen University), Ziheng He(Central South University)
Molecular Cancer
January 30, 2020
10.1186/s12943-020-1144-6
Cited by 333

Related Papers

The cancer metabolic reprogramming and immune response
|Molecular Cancer|2021|1.3k
Circular RNAs function as ceRNAs to regulate and control human cancer progression
|Molecular Cancer|2018|1.1k
Neoantigen vaccine: an emerging tumor immunotherapy
|Molecular Cancer|2019|718
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|677
Effects of environmental pollutants on gut microbiota
|Environmental Pollution|2017|662